## **ERCUSYN Newsletter**


August 2019

The **ERCUSYN** (European Register on Cushing's Syndrome) project, is aimed at registering clinical data on patients with Cushing's syndrome throughout Europe, with the following **objectives**:

1) to set up a European Register on the diagnosis, management, quality of life and outcomes of patients affected by Cushing's syndrome across European countries;

2) to define relevant health indicators and information to develop epidemiological data at EU level;

- 3) to collect data on the impact of Cushing's syndrome on Health-related Quality of Life;
- 4) to define the optimal diagnosis strategy and the short and long term therapeutic goals;
- 5) to increase awareness about the disease by disseminating what has been learnt from the project;
- 6) to evaluate the persistent consequences of having suffered Cushing's syndrome



By August 2019, **1864 patients** have been included, with partners from **64 centers** in **29 countries** (database developed by Lohmann & Birkner Health Care Consulting GmbH –L&B). See link to map with details of all centers:

http://www.lohmann-birkner.de/ercusyn/wEnglish/gmap/index.php

## Invitation to join the project:

The ERCUSYN project welcomes European centers of excellence who work with CS to join and contribute to the project, if they are prepared to include patients and update their outcome periodically. If interested please contact asantos@ercusyn.eu

Scientific Steering Committee: Susan M Webb, Christian Strasburger, Peter Trainer, Antoine Tabarin and John Newell-Price Supervising board: Jens Bollerslev, Michael Buchfelder, Ezio Ghigo and John Wass Project Manager: Alicia Santos; Quality Data Manager: Elena Valassi; Database support: Holger Franz, Daniel Thyroke, L&B

For any further information please contact:<u>asantos@</u> <u>ercusyn.eu</u>



The ERCUSYN project has received funding from the European Commission (PHP 800200) and is supported by the ESE and by unrestricted support from Novartis, Ipsen and HRA.